Europe’s First Alzheimer’s Treatment: Will Leqembi Live Up to Expectations?

Bélinda Ibrahim, 11:00 - Reading : 3 minute(s)

Alzheimer Treatment Leqembi Europe Science

After decades of research and broken promises, the arrival of Leqembi (lecanemab) marks a symbolic milestone in the fight against Alzheimer’s. Developed by Eisai and Biogen, this monoclonal antibody has just been approved in the European Union for the treatment of early-stage Alzheimer’s. For the first time, a drug aims to slow the progression ...